Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal

Luigi Gallimberti, Fabrizio Schifano, Giovanni Forza, Lorella Miconi, S. Davide Ferrara

Research output: Contribution to journalArticle

Abstract

This paper describes the role of gamma-hydroxybutyric acid (GHB) in the treatment of opiate withdrawal syndrome. In the two patients described, after having abruptly withdrawn from long-term methadone treatment, GHB was orally administered (each dose given every 4-6 h) for 8-9 days. The GHB showed both a high efficacy (some mild and transient symptoms attributable to opiate withdrawal were observed, but only in the first days of therapy) and a good tolerability (no clinical phenomena interpreted as GHB side effects were found). These results could be of interest in improving the pharmacological treatment of drug addiction.

Original languageEnglish
Pages (from-to)113-114
Number of pages2
JournalEuropean Archives of Psychiatry and Clinical Neuroscience
Volume244
Issue number3
DOIs
Publication statusPublished - Sep 1994

Fingerprint

Opiate Alkaloids
Methadone
Therapeutics
Substance-Related Disorders
Pharmacology
4-hydroxybutyric acid

Keywords

  • Drug addiction
  • Gamma-hydroxybutyrate
  • Opiate dependence
  • Opiate withdrawal

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal. / Gallimberti, Luigi; Schifano, Fabrizio; Forza, Giovanni; Miconi, Lorella; Ferrara, S. Davide.

In: European Archives of Psychiatry and Clinical Neuroscience, Vol. 244, No. 3, 09.1994, p. 113-114.

Research output: Contribution to journalArticle

Gallimberti, Luigi ; Schifano, Fabrizio ; Forza, Giovanni ; Miconi, Lorella ; Ferrara, S. Davide. / Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal. In: European Archives of Psychiatry and Clinical Neuroscience. 1994 ; Vol. 244, No. 3. pp. 113-114.
@article{1e559aed062745528e62ee6e215728b4,
title = "Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal",
abstract = "This paper describes the role of gamma-hydroxybutyric acid (GHB) in the treatment of opiate withdrawal syndrome. In the two patients described, after having abruptly withdrawn from long-term methadone treatment, GHB was orally administered (each dose given every 4-6 h) for 8-9 days. The GHB showed both a high efficacy (some mild and transient symptoms attributable to opiate withdrawal were observed, but only in the first days of therapy) and a good tolerability (no clinical phenomena interpreted as GHB side effects were found). These results could be of interest in improving the pharmacological treatment of drug addiction.",
keywords = "Drug addiction, Gamma-hydroxybutyrate, Opiate dependence, Opiate withdrawal",
author = "Luigi Gallimberti and Fabrizio Schifano and Giovanni Forza and Lorella Miconi and Ferrara, {S. Davide}",
year = "1994",
month = "9",
doi = "10.1007/BF02191883",
language = "English",
volume = "244",
pages = "113--114",
journal = "European Archives of Psychiatry and Clinical Neuroscience",
issn = "0940-1334",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal

AU - Gallimberti, Luigi

AU - Schifano, Fabrizio

AU - Forza, Giovanni

AU - Miconi, Lorella

AU - Ferrara, S. Davide

PY - 1994/9

Y1 - 1994/9

N2 - This paper describes the role of gamma-hydroxybutyric acid (GHB) in the treatment of opiate withdrawal syndrome. In the two patients described, after having abruptly withdrawn from long-term methadone treatment, GHB was orally administered (each dose given every 4-6 h) for 8-9 days. The GHB showed both a high efficacy (some mild and transient symptoms attributable to opiate withdrawal were observed, but only in the first days of therapy) and a good tolerability (no clinical phenomena interpreted as GHB side effects were found). These results could be of interest in improving the pharmacological treatment of drug addiction.

AB - This paper describes the role of gamma-hydroxybutyric acid (GHB) in the treatment of opiate withdrawal syndrome. In the two patients described, after having abruptly withdrawn from long-term methadone treatment, GHB was orally administered (each dose given every 4-6 h) for 8-9 days. The GHB showed both a high efficacy (some mild and transient symptoms attributable to opiate withdrawal were observed, but only in the first days of therapy) and a good tolerability (no clinical phenomena interpreted as GHB side effects were found). These results could be of interest in improving the pharmacological treatment of drug addiction.

KW - Drug addiction

KW - Gamma-hydroxybutyrate

KW - Opiate dependence

KW - Opiate withdrawal

UR - http://www.scopus.com/inward/record.url?scp=0028048867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028048867&partnerID=8YFLogxK

U2 - 10.1007/BF02191883

DO - 10.1007/BF02191883

M3 - Article

C2 - 7803523

AN - SCOPUS:0028048867

VL - 244

SP - 113

EP - 114

JO - European Archives of Psychiatry and Clinical Neuroscience

JF - European Archives of Psychiatry and Clinical Neuroscience

SN - 0940-1334

IS - 3

ER -